

March 29, 2017
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President & Chief Executive Officer
 (Securities Code: 4582)

**Notice of Appointment of Members of the Board of Directors,
 Members of the Audit & Supervisory Board, and the Corporate Officers**

TOKYO, Japan, March 29, 2017 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) announced today that a resolution was passed at the 12th Ordinary General Meeting of Shareholders held today for the reappointment of four of the six members of the Board of Directors, and for two members of the Board of Directors and two members of the Audit & Supervisory Board to be newly appointed, as listed below. The reappointment of the Representative Director, the appointment of the new Representative Director, and appointment of the Corporate Officers was subsequently approved at the Board of Directors' meeting which convened following the close of this Ordinary General Meeting of Shareholders.

1. Members of the Board of Directors

Name	Title
Fuminori Yoshida	Representative Director
Kazuo Asakawa (newly appointed)	Representative Director
Naoko Iino	Outside Director
Sumio Ariyoshi (newly appointed)	Outside Director
George Morstyn	Outside Director
Milton Grannatt	Outside Director

* Mr. Lowell Sears and Mr. George Vandeman resigned upon expiration of their term of office at the closing of the 12th Ordinary General Meeting of Shareholders held on March 29, 2017.

2. Members of the Audit & Supervisory Board

Name	Title
Kiyoshi Watanabe (newly appointed)	Full - time Audit & Supervisory Board Member (Outside)
Shigetoshi Matsumoto (newly appointed)	Audit & Supervisory Board Member (Outside)

* Mr. Takeshi Masuda and Mr. Chikara Shimazaki resigned at the closing of the 12th Ordinary General Meeting of Shareholders held on March 29, 2017.

3. Corporate Officers

Name	Title
Fuminori Yoshida	Corporate Officer, President and Chief Executive Officer
Kazuo Asakawa	Corporate Officer, Executive Vice President and Chief Operating Officer
Tsutomu Abe	Corporate Officer

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125